公开(公告)号：EP1979348A2

公开(公告)日：2008-10-15

申请号：EP06848055.7

申请日：2006-12-20

Applicant: ABBOTT LABORATORIES

Inventor： BETEBENNER, David, A. ,  DEGOEY, David, A. ,  MARING, Clarence, J. ,  KRUEGER, Allan, C. ,  IWASAKI, Nobuhiko ,  ROCKWAY, Todd, W. ,  COOPER, Curt, S. ,  ANDERSON, David, D. ,  DONNER, Pamela, L. ,  GREEN, Brian, E. ,  KEMPF, Dale, J. ,  LIU, Dachun ,  MCDANIEL, Keith,F. ,  MADIGAN, Darold, L. ,  MOTTER, Christopher, E. ,  PRATT, John, K. ,  SHANLEY, Jason, P. ,  TUFANO, Michael, D. ,  WAGNER, Rolf ,  ZHANG, Rong ,  MOLLA, Akhteruzzaman ,  MO, Hongmei ,  PILOT-MATIAS, Tami, J. ,  MASSE, Sherie, VL. ,  CARRICK, Robert, J. ,  HE, Weping ,  LU, Liangjun ,  GRAMPOVNIK, David, J.

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D495/04 ,  C07D513/04

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

公开(公告)号：EP1979348B1

公开(公告)日：2012-01-18

申请号：EP06848055.7

申请日：2006-12-20

Applicant: ABBOTT LABORATORIES

Inventor： BETEBENNER, David, A. ,  DEGOEY, David, A. ,  MARING, Clarence, J. ,  KRUEGER, Allan, C. ,  IWASAKI, Nobuhiko ,  ROCKWAY, Todd, W. ,  COOPER, Curt, S. ,  ANDERSON, David, D. ,  DONNER, Pamela, L. ,  GREEN, Brian, E. ,  KEMPF, Dale, J. ,  LIU, Dachun ,  MCDANIEL, Keith,F. ,  MADIGAN, Darold, L. ,  MOTTER, Christopher, E. ,  PRATT, John, K. ,  SHANLEY, Jason, P. ,  TUFANO, Michael, D. ,  WAGNER, Rolf ,  ZHANG, Rong ,  MOLLA, Akhteruzzaman ,  MO, Hongmei ,  PILOT-MATIAS, Tami, J. ,  MASSE, Sherie, VL. ,  CARRICK, Robert, J. ,  HE, Weping ,  LU, Liangjun ,  GRAMPOVNIK, David, J.

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D495/04 ,  C07D513/04

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.